Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Non-Current Assets (2020 - 2025)

Bioventus (BVS) has disclosed Non-Current Assets for 6 consecutive years, with $410.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 9.2% year-over-year to $410.7 million, compared with a TTM value of $1.7 billion through Dec 2025, up 40.37%, and an annual FY2025 reading of $410.7 million, down 9.2% over the prior year.
  • Non-Current Assets was $410.7 million for Q4 2025 at Bioventus, down from $420.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.1 billion in Q4 2022 and bottomed at -$308.9 million in Q2 2024.
  • Average Non-Current Assets over 5 years is $448.5 million, with a median of $436.8 million recorded in 2025.
  • The sharpest move saw Non-Current Assets surged 240.59% in 2021, then crashed 127.98% in 2023.
  • Year by year, Non-Current Assets stood at $962.8 million in 2021, then grew by 14.26% to $1.1 billion in 2022, then tumbled by 50.65% to $542.9 million in 2023, then decreased by 16.68% to $452.3 million in 2024, then decreased by 9.2% to $410.7 million in 2025.
  • Business Quant data shows Non-Current Assets for BVS at $410.7 million in Q4 2025, $420.7 million in Q3 2025, and $431.6 million in Q2 2025.